Kolkata, 4th July, 2025 :
Suraksha Diagnostics, one of the leading diagnostic chains in Eastern India, has officially launched the region’s largest and most advanced state-of-the-art Genomics Laboratory. The grand inauguration event was held in Kolkata and was attended by Prof. Sukumar Mukherjee, a distinguished rheumatologist with over 35 years of clinical experience and a mentor to Suraksha Diagnostics.
The newly inaugurated Genomics Lab represents a significant step forward in precision diagnostics and personalized medicine. Equipped with advanced technologies such as Cytogenetics, Chromosomal Microarray Technology, Sanger Sequencing, and Multiple Next-Generation Sequencers (NGS), the lab is designed to deliver comprehensive genomic testing for early diagnosis, predictive analytics, and tailored treatment plans.
Dr. Somnath Chatterjee, Chairman and Joint Managing Director, Suraksha Diagnostics, commented on the launch:
“A transformative shift is underway in healthcare, driven by genomic science. Suraksha Diagnostics is committed to being at the forefront of this movement bringing the power of genomic data to everyday clinical decisions, from fetal medicine to oncology and rare disease diagnostics.”
Ms. Ritu Mittal, CEO and Managing Director, emphasized the lab’s role in healthcare decision-making in Eastern India:
“We provide an end-to-end solution for prenatal and genetic diagnostics, maintaining the highest quality standards. Our lab eliminates the need to send samples outside the region, enabling faster, more accurate, and cost-effective care for clinicians and patients alike.”
Significant Investment in India’s Precision Medicine Ecosystem
Suraksha Diagnostics has invested ₹22 crores to establish the Genomics Lab, with an additional ₹46 crore investment planned over the next two years. This will support the creation of one of Asia’s most advanced genomics laboratories, enhancing access to high-quality genetic diagnostics in West Bengal, Eastern and North-Eastern India.
The global genetic testing market, currently valued at USD 38.77 billion (2024), is projected to grow to USD 186.64 billion by 2035 (CAGR 22.5%). Suraksha’s initiative aligns with this global trend and supports national healthcare priorities such as rare disease identification, newborn screening, and preventive genomics.
Applications in Fetal Medicine and Oncology
The Genomics Lab supports early detection of chromosomal disorders such as Down syndrome, Edwards syndrome, Patau syndrome, and other genetic anomalies, offering critical insights for expectant parents and pediatric care providers.
In addition, the lab advances Onco-genomics with hereditary cancer panels for breast, ovarian, and colorectal cancers, enabling clinicians to identify genetic predispositions and provide personalized oncology treatment. The integration of NGS-based oncology panels enables the detection of actionable mutations, making precision therapies more accessible across Eastern India.
About Suraksha Diagnostics
Founded in 1992, Suraksha Diagnostics has grown into a leading diagnostics provider, offering more than 2,300 tests across pathology, radiology, and medical consultancy. The company operates 59 diagnostic centres, 166 sample collection points, eight satellite laboratories, and a central reference lab. Its presence spans West Bengal, Bihar, Assam, and Meghalaya, with strong investments in AI-enabled smart labs and digital platforms to enhance operational efficiency and patient care.
In December 2024, Suraksha Diagnostics successfully completed its Initial Public Offering (IPO), raising ₹846.25 crore and achieving a 1.27x subscription, reflecting strong investor confidence in its strategic direction and growth.
